Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-03
2007-07-03
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S259300, C514S267000, C514S293000, C514S303000, C514S393000, C544S281000, C546S082000, C546S084000, C546S118000, C548S250000, C548S258000, C548S262400, C548S303100
Reexamination Certificate
active
10771766
ABSTRACT:
The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”)useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
REFERENCES:
patent: 3865836 (1975-02-01), Van Gelder et al.
patent: 4210659 (1980-07-01), Stahle et al.
patent: 4532243 (1985-07-01), Tully
patent: 4551530 (1985-11-01), Dusza et al.
patent: 6191136 (2001-02-01), Marban
patent: 6194419 (2001-02-01), Furuya et al.
patent: 6437148 (2002-08-01), Frutos et al.
patent: 6492408 (2002-12-01), Wu et al.
patent: 0 778 277 (1997-06-01), None
patent: 0 812 831 (1997-12-01), None
patent: 0 902 029 (1999-03-01), None
patent: 0 970 958 (2000-01-01), None
patent: WO 97/29109 (1997-08-01), None
patent: WO 98/35967 (1998-08-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/10350 (1999-03-01), None
patent: WO 99/67247 (1999-12-01), None
patent: WO 00/01675 (2000-01-01), None
patent: WO 00/01697 (2000-01-01), None
patent: WO 00/39127 (2000-07-01), None
patent: WO 00/59907 (2000-10-01), None
patent: WO 00/59908 (2000-10-01), None
patent: WO 01/007440 (2001-02-01), None
Vippagunta, S.R. et. al., “Crystalline solids”, Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
Dunn, et al., “Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?”, Brain Research Reviews, 15, 1990, pp. 71-100.
Gulyas, et al., “Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor,” Prac. Natl. Acad. Sci. USA, 92, 1995, pp. 10575-10579.
McCarthy, et al., “Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications,” Current Pharmaceutical Design, 5, 1999, pp. 289-315.
Holsboer, “The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety,” Journal of Psychiatric Research, 33, 1999, pp. 181-214.
Banki, et al., “CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse,” European Neuropsychopharmacology, 2, 1992, pp. 107-113.
Zobel, et al., “Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression, the first 20 patients treated,” Journal of Psychiatric Research, 34, 2000, pp. 171-181.
Webster, et al., “Corticotropin-Releasing Hormone and Inflammation,” Annals New York Academy of Sciences, 840, 1998, pp. 21-62.
Gilligan, et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents,” Journal of Medicinal Chemistry, 43, 9, 2000, pp. 1641-1660.
McCarthy, et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents,” Annual Reports in Medicinal Chemistry, 34, 1999, pp. 11-20.
Dasgupta Bireshwar
Dubowchik Gene M.
Macor John E.
Vrudhula Vivekananda M.
Bristol--Myers Squibb Company
Makujina Shah R.
Truong Tamthom N.
Wilson James O.
LandOfFree
Imidazolyl derivatives as corticotropin releasing factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolyl derivatives as corticotropin releasing factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl derivatives as corticotropin releasing factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810003